Update: sol-gel reports second quarter 2024 financial results and provides corporate updates

Following recent transactions and cost-cutting efforts, sol-gel's cash runway is expected to extend into the first quarter of 2026 ongoing phase 3 clinical trial of sgt-610 for gorlin syndrome with over 30 clinical sites activated; top-line results are expected by the second quarter of 2026 sgt-210 proof-of-concept study in patients suffering from darier disease, a significant unmet medical need in dermatology, is ongoing sol-gel sells its rights in the abbreviated new drug application (anda) drug product generic to zoryve® cream (roflumilast cream 0.3%) following management realignment, mr. mori arkin, the company's executive chairman and controlling shareholder to be appointed as company's interim ceo as of january 1, 2025, subject to shareholders approval sol-gel recently signed license agreements with respect to twyneo and epsolay in europe and south africa and is negotiating additional license deals in latin america and other territories ness ziona, israel, aug. 17, 2024 (globe newswire) -- sol-gel technologies, ltd.
SLGL Ratings Summary
SLGL Quant Ranking